<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9296">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985918</url>
  </required_header>
  <id_info>
    <org_study_id>BeijingCYH-ICU-004</org_study_id>
    <nct_id>NCT02985918</nct_id>
  </id_info>
  <brief_title>High-intensity Versus Conventional-intensity Noninvasive Positive Pressure Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: the HAPPEN Study (HAPPEN)</brief_title>
  <official_title>High-intensity Versus Conventional-intensity Noninvasive Positive Pressure Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: a Multicenter, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the present study is to verify whether, as compared with
      conventional-intensity noninvasive positive pressure ventilation, high-intensity noninvasive
      positive pressure ventilation may more effective in correcting hypercapnia, hence reducing
      the need for intubation and improving survival in patients with acute exacerbation of
      chronic obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intubation rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The decrements of PaCO2 measured at 2 hours after enrollment.</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The decrements of PaCO2 measured at 6 hours after enrollment.</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The decrements of PaCO2 measured at 24 hours after enrollment.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The decrements of PaCO2 measured at 48 hours after enrollment.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality rate</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital survival rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality rate</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication related to NPPV</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Acute Exacerbation of Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>High-intensity NPPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive high-intensity noninvasive positive pressure ventilation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional-intensity NPPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will receive conventional-intensity noninvasive positive pressure ventilation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High-intensity NPPV</intervention_name>
    <description>The patients will receive noninvasive positive pressure ventilation using S/T mode. The inspiratory positive airway pressure will be initially set at 10 cmH2O, and will be continuously adjusted by increments/decrements of 1-2 cmH2O, according to subjects' tolerance (up to 30 cmH2O), to obtain a VT of 15 mL/kg of predicted body weight, and to achieve normocapnia as possible as it can.</description>
    <arm_group_label>High-intensity NPPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional-intensity NPPV</intervention_name>
    <description>The patients will receive noninvasive positive pressure ventilation using S/T mode. The inspiratory positive airway pressure will be initially set at 10 cmH2O, and will be continuously adjusted by increments/decrements of 1-2 cmH2O, according to subjects' tolerance (up to 20 cmH2O), to obtain a VT of 10 mL/kg of predicted body weight.</description>
    <arm_group_label>Conventional-intensity NPPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD according to the criteria of the Global Initiative for Chronic
             Obstructive Lung Disease in 2016

          -  Presence of acute exacerbation

          -  Arterial pH &lt;7.35 with arterial carbon dioxide tension &gt;45 mmHg

        Exclusion Criteria:

          -  age &lt;18 years

          -  Excessive amount of respiratory secretions or weak cough

          -  Upper airway obstruction

          -  Recent oral, facial, or cranial trauma or surgery

          -  Recent gastric or esophageal surgery

          -  Severe abdominal distension

          -  Active upper gastrointestinal bleeding

          -  Cardiac or respiratory arrest;

          -  Arterial oxygen tension/fraction of inspired oxygen (PaO2/FiO2) &lt;150 mmHg

          -  Pneumothorax

          -  Severe ventricular arrhythmia or myocardial ischemia

          -  Severe hemodynamic instability despite fluid repletion and use of vasoactive agents

          -  Severe metabolic acidosis

          -  Refusal to receive NPPV

          -  Lack of cooperation

          -  Intolerance of NPPV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zujin Luo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zujin Luo, MD</last_name>
    <email>xmjg2002@163.com</email>
  </overall_contact>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 12, 2016</lastchanged_date>
  <firstreceived_date>December 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Zujin Luo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
